Print Listing - PROFITABLE DNA NUTRITION PLATFORM, 10,000 USERS

NOT DISCLOSED, Wyoming

Asking Price	$1,199,000	Year Established	2018
Annual Revenue	$546,313	Reason for Selling	Other Personal Interests
Annual P/L	$0	Attention	Tony Keane
Annual Cash Flow	$318,521	Listing Number	1014727
# of Employees		Business Category	Technology: Internet, Websites

Business Overview:

PROFITABLE DNA NUTRITION PLATFORM, 10,000 USERS, 59% SDE MARGIN

A profitable, founder-built precision-nutrition platform that has sold its core product every day for eight years.

The company translates a customer's DNA into a practical, personalized way of eating. A proprietary algorithm classifies each customer into one of twenty named diet types, then generates a personalized meal plan and nutrition protocol built around how that individual actually metabolizes fat, carbohydrate, protein, caffeine, histamine, and dietary cholesterol. On top of that core sits a growing library of premium health reports — cardiovascular, methylation, micronutrient, longevity, sleep, and more — sold as an annual membership currently held by approximately 1,000 members, plus a branded supplement line matched to the genetic results.

This is a product with demonstrated durable product-market fit. It launched in 2018, has served thousands of customers, and has generated revenue continuously since. The twenty-diet-type framework is what customers connect with, talk about, and return for: an identity and a plan rather than a raw data dump. Customer acquisition runs on SEO, organic search, email, and word of mouth, supported by HSA/FSA eligibility and inbound demand from clinics and integrative-medicine practitioners.

The business is profitable and capital efficient. Revenue grew from under $60,000 to $555,300 in three years while remaining profitable every year. In 2025 it generated $327,200 in seller's discretionary earnings — a 59% SDE margin — on a fully remote operation with no full-time employees and approximately 79% gross margins.

The platform has also proven it can extend. A 2025 supplement line and a 2026 environmental-genomics release were both built and shipped on modest budgets using the existing architecture, and a consented research cohort has been accumulating alongside the core business. These represent optionality on top of a proven cash-generating core.

Highlights:

$555,300 revenue in 2025 | $327,200 SDE | ~79% gross margins
Eight consecutive years of sales on the core DNA nutrition product, launched 2018
~110% three-year revenue CAGR (FY22 $58.5K → FY25 $555.3K); SDE up from $29.9K to $327.2K
Proprietary twenty-diet-type taxonomy built on 200+ vetted genetic factors, each carrying an internal Science Grade derived from a two-year peer-reviewed literature review
AI engine generating personalized meal plans and nutrition protocols directly from genetic results
Approximately 1,000 members paying annual fees — an established subscription layer built without a dedicated conversion program
Two acquisition paths into the core product: physical test kits fulfilled through a CLIA-certified lab, and near-zero-COGS analysis of raw data uploaded from 23andMe and Ancestry
2025 supplement line with repeat-purchase behavior
Demonstrated B2B demand from wellness clinics, IV clinics, functional-medicine providers, and physicians
Strong SEO, low CAC, HSA/FSA eligible
Lean and remote: owner part-time plus four independent contractors, no physical overhead
Consented, transferable genome + environment research dataset — a monetization path not yet activated

Property Features and Assets:

The company was built science-first. Before launch, the founding team — led by a head of research and lead geneticist — spent the better part of two years reviewing hundreds of peer-reviewed studies on genetics and nutrition, ranking genes by scientific validation and assigning each an internal Science Grade. That research became the backbone of the nutrition algorithm and the twenty-diet-type framework. The product launched in 2018 anchored on a central scientific question: why do people respond so differently to the same foods — for example, large versus negligible LDL changes on the same saturated-fat intake? Eight years later, that question still drives the roadmap. The company has since layered a premium health-report membership, a supplement line, and an environmental-genomics module onto the same core platform, each reusing the existing infrastructure rather than requiring a rebuild.

Market Competition and Expansion:

Expand the supplement line and complete the Amazon marketplace launch. The core analysis already tells every customer which supplements matter for them; the fulfillment of that recommendation is currently mostly unmonetized. This is the seller's view of the nearest-term opportunity. • Push the raw-data upload channel. Millions of consumers hold 23andMe and Ancestry data with no ongoing use for it. This channel carries near-zero COGS and is undermarketed. • Formalize the B2B channel. Demand from clinics, functional-medicine practices, universities, and sports teams is already arriving inbound. No structured partner program, pricing tier, or practitioner dashboard exists yet. • Add reports to the membership library. Each new report increases the value of the existing ~1,000-member base with no change to acquisition cost. The architecture is purpose-built for this. • Deepen the membership base. Roughly 1,000 of ~10,000 registered users currently subscribe, achieved without a dedicated conversion program. A buyer with lifecycle-marketing capability has clear headroom here. • Activate data licensing. The consent framework already permits commercial research partnerships — an untapped, high-margin revenue line. • Press the environmental-genomics position if the buyer's strategy favors it — differentiated and largely uncontested. • International and partnership expansion, leveraging a high-margin digital delivery model. • Market tailwind: the personalized nutrition and nutrigenomics market is projected to grow at a 17.4% compound annual rate through 2030 (Grand View Research). Business is positioned well to be a serious competitor in the space. Eight years of proven demand, not a launch story. The core product has sold continuously since 2018 and has personalized nutrition for thousands of customers. This is not a business asking a buyer to underwrite an unproven thesis — the demand is established, measured, and repeatable. A framework customers actually love. The twenty diet types give an abstract genetic result a name, a personality, and a meal plan. That is why the product retains attention in a category where most competitors deliver a PDF the customer reads once. It supports word-of-mouth acquisition, repeat purchase into the membership tier, and a low blended customer acquisition cost. Profitable and growing — rare in consumer genomics. Most companies in this category burn cash. This one has compounded revenue and earnings together to a 59% SDE margin while fully self-funded. An established recurring layer. Approximately 1,000 customers hold paid annual memberships to the premium health report library, accumulated organically at the point of analysis rather than through a dedicated conversion campaign. A buyer inherits this layer rather than having to build it. Earnings understate true owner’s cash flow. Roughly $293,300 has been invested in product development throughout the company's life, expensed as incurred and largely elective. The platform costs very little to simply operate. A new owner can convert that spending into cash flow or keep compounding growth. (See "The Earnings Story.") A real technology and data asset, not a reseller. The value sits in a proprietary nutrition algorithm and diet-type taxonomy, an AI protocol engine, a library of premium health reports, and a consented research dataset — all owned, all transferable.

Additional Details:

The property is Leased.
This is not homebased business opportunity.
This is not a franchise resale opportunity